Price
$2.89
Increased by +2.85%
Dollar volume (20D)
3.73 M
ADR%
8.72
Shares float
82.38 M
Shares short
10.12 M [12.29%]
Shares outstanding
109.71 M
Market cap
308.30 M
Beta
1.26
Price/earnings
N/A
20D range
2.25 3.11
50D range
1.60 3.11
200D range
1.28 7.85

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.

The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.

In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis.

The company was incorporated in 2011 and is headquartered in Brisbane, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 12, 25 -0.37
Decreased by -76.19%
-0.34
Decreased by -8.82%
Mar 24, 25 -0.33
Increased by +8.33%
-0.29
Decreased by -12.51%
Nov 11, 24 -0.25
Increased by +41.86%
-0.26
Increased by +3.85%
Aug 12, 24 -0.23
Increased by +51.06%
-0.23
May 13, 24 -0.21
Increased by +59.62%
-0.34
Increased by +38.24%
Mar 26, 24 -0.36
Increased by +25.00%
-0.44
Increased by +18.18%
Nov 13, 23 -0.43
Increased by +15.69%
-0.50
Increased by +14.00%
Aug 7, 23 -0.47
Increased by +51.04%
-0.54
Increased by +12.96%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 0.00
Decreased by N/A%
-54.36 M
Decreased by -115.90%
Decreased by N/A%
Decreased by N/A%
Dec 31, 24 0.00
Decreased by -100.00%
-48.59 M
Decreased by -74.21%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 0.00
Decreased by N/A%
-34.82 M
Decreased by -7.21%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by N/A%
-29.61 M
Increased by +15.85%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by N/A%
-25.18 M
Increased by +29.23%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 4.87 M
Increased by +N/A%
-27.89 M
Increased by +13.03%
Decreased by -573.18%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-32.48 M
Increased by +4.57%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-35.19 M
Increased by +4.55%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY